- Aadi Bioscience press release (NASDAQ:AADI): Q3 GAAP EPS of -$0.68.
- Revenue of $4.24M.
- Cash, cash equivalents and short-term investments as of September 30, 2022 were $183.0 million as compared to $149.0 million as of December 31, 2021, which is expected to fund operations into 2025 based on current plans.
Aadi Bioscience GAAP EPS of -$0.68, revenue of $4.24M
Recommended For You
More Trending News
About AADI Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AADI | - | - |
Aadi Bioscience, Inc. |